Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs DEGARELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Treatment of advanced prostate cancer
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Hepatic via hydrolysis of the acetate ester; no significant CYP450 involvement.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
99% bound; primary binding protein: albumin.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Approximately 1 L/kg, indicating extensive distribution into tissues.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Subcutaneous: approximately 100% for the depot formulation; not available orally due to peptide degradation.
No dosage adjustment required for renal impairment.
No dose adjustment required for GFR ≥15 m L/min. Insufficient data for GFR <15 m L/min or dialysis; use caution.
No dosage adjustment required for hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
Safety and efficacy in pediatric patients have not been established; use not recommended.
Safety and efficacy not established in pediatric patients; no recommended dosing.
No specific dosage adjustment required; use same dosing as for younger adults.
No specific dose adjustment required; similar efficacy and safety observed in elderly patients (≥65 years) compared to younger adults.
No FDA boxed warning.
None
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity reactions including anaphylaxis and angioedema,QT interval prolongation,Laboratory test interference with gonadotropin and gonadal steroid assays,Injection site reactions including pain and erythema,Bone density loss,Hyperglycemia and increased risk of diabetes
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Hypersensitivity to degarelix or any component of the formulation,Pregnancy (potential fetal harm)
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
No specific food interactions have been identified. Degarelix is administered parenterally and does not interact with dietary components. Avoid grapefruit juice if concurrent QT-prolonging drugs are used, but not a direct interaction with degarelix.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential for fetal androgen deprivation leading to ambiguous genitalia in male fetuses.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
No data available on excretion in human milk; potential for serious adverse effects in nursing infants; discontinue breastfeeding or discontinue drug.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
No dose adjustments are applicable as degarelix is contraindicated in pregnancy; therapy must be discontinued if pregnancy occurs.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Degarelix acetate is a Gn RH antagonist used for advanced prostate cancer. It provides rapid testosterone suppression without the initial testosterone surge seen with Gn RH agonists. Monitor serum testosterone and PSA levels; castrate levels (<50 ng/d L) typically achieved within 3 days. Injection site reactions are common; rotate injection sites (abdomen, thigh, buttock). Avoid in patients with known QT prolongation or concurrent QT-prolonging drugs. Contraindicated in women and children.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Degarelix is given as a subcutaneous injection by a healthcare provider every month (or every 2 months for maintenance dose) to treat advanced prostate cancer.,Do not miss scheduled injections because consistent dosing is needed to keep testosterone levels low.,Common side effects include injection site pain, redness, or swelling; hot flashes; increased liver enzymes; and weight gain.,Report signs of allergic reaction (rash, itching, difficulty breathing) or prolonged QT interval (fainting, palpitations) to your doctor immediately.,Degarelix may cause bone thinning; discuss calcium and vitamin D supplementation with your doctor.,This drug can cause harm to a fetus; not for use in women or children.
No interactions on record
"Asenapine, a second-generation antipsychotic, is associated with dose-dependent QTc interval prolongation due to its inhibitory effects on cardiac potassium channels (specifically IKr). Degarelix, a GnRH antagonist used in prostate cancer, may also cause QTc prolongation, likely through hormonal suppression mechanisms. Coadministration can result in additive QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with pre-existing risk factors."
"Dolasetron, a 5-HT3 receptor antagonist, is known to cause dose-dependent prolongation of the QT interval by blocking cardiac potassium channels. When coadministered with Degarelix, a GnRH receptor antagonist that also reduces testosterone levels and can induce QT prolongation via electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) or direct cardiac effects, the risk of additive QT prolongation is increased. This may lead to a higher propensity for torsade de pointes and other ventricular arrhythmias, particularly in patients with pre-existing risk factors."
"Cabazitaxel is a taxane antineoplastic agent that undergoes extensive hepatic metabolism via CYP3A4/5 and is a substrate of P-glycoprotein. Degarelix, a GnRH antagonist, has no known direct metabolic interaction with Cabazitaxel but may theoretically increase the risk of QT prolongation when combined with other drugs. However, the baseline description is vague; the interaction is not well-established and possibly refers to additive myelosuppression or cardiovascular effects from overlapping toxicities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs DEGARELIX ACETATE, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. DEGARELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and DEGARELIX ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of DEGARELIX ACETATE is: Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and DEGARELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. DEGARELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.